Primary Outcome Measures:
- LAR area under the curve from 3 to 7 hours (AUC(3-7 hr)) expressed as % change in FEV1 from the prechallenge value of FEV1 taken from 3 to 7 hours postallergen challenge, following 9 days pretreatment with SCH 527123. [ Time Frame: Visits 9 and 14 ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Maximum percent fall in FEV1 during the late response following 9 days of pretreatment with SCH 527123. [ Time Frame: Visits 9 and 14 ] [ Designated as safety issue: Yes ]
- LAR AUC(3-7 hr), expressed as actual change in FEV1 from preallergen FEV1 taken from 3 to 7 hours postallergen challenge, following 9 days of pretreatment with SCH 527123. [ Time Frame: Visits 9 and 14 ] [ Designated as safety issue: Yes ]
- Changes in airway responsiveness as measured by methacholine PC20 24 hours postallergen challenge. [ Time Frame: Visits 9 and 14 ] [ Designated as safety issue: Yes ]
- Reduction in sputum neutrophils and eosinophils at 7 and 24 hours postallergen challenge. [ Time Frame: Visits 9 and 14 ] [ Designated as safety issue: Yes ]
- Attenuation of EAR (maximum percent fall in FEV1 from preallergen FEV1 0-2 hours postchallenge) and EAR UC(0-2 hr) following 9 days of pretreatment with SCH 527123. [ Time Frame: Visits 9 and 14 ] [ Designated as safety issue: Yes ]
- Changes in interleukin 8 (IL-8), myeloperoxidase (MPO), neutrophil elastase, and eosinophil cationic protein (ECP) levels in sputum at 7 and 24 hours postallergen challenge. [ Time Frame: Visits 9 and 14 ] [ Designated as safety issue: Yes ]
- Safety and tolerability as measured by peripheral neutrophil counts, asthma symptoms, frequency of use of rescue medication, PFTs, ECGs, labs, and AEs. [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]
To evaluate the effect of SCH 527123 treatment on allergen-induced late asthmatic response (LAR) in subjects with mild asthma.